Furthermore, tofacitinib was evaluated in a Phase Ib clinical trial (NCT02535689) that enrolled patients with mild to moderate SLE, stratified based on their STAT4 genetic risk profile. This evidence concerns the gene STAT4 and systemic lupus erythematosus.